PR

Perrigo Company plc

PRGOHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic · Last scanned Sep 9, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$4.25B
-2.8% YoY
Net Income
-$1.43B
-729.7% YoY
EBITDA
-$797.9M
-284.3% YoY
Free Cash Flow
$437.2M

Scan Results

Daily timeframe
5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OverboughtRSI 73.7, above 70, stock may be overbought
Sep 2 RSI OverboughtRSI 74.2, above 70, stock may be overbought
About Perrigo Company plc

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. At a $2.02B market cap, Perrigo Company plc ranks as a mid-cap company within healthcare. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Where PRGO stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, PRGO finished 29.26% above its 150-day moving average ($11.21) and 24.48% above its 200-day moving average ($11.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is PRGO overbought or oversold?

At the September 3, 2026 close, PRGO's RSI(14) was 73.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.02B
Fwd P/E6.08
EPS$-12.29
Beta0.60
52W Change-32.6%
Dividend Yield7.77%
ROE-48.8%
Analysis

The company holds $399.7M in cash, though total debt stands at $3.48B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $437.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -48.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.0% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $4.45B (2022) to $4.25B (2025).

The relatively low beta of 0.60 suggests PRGO is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Perrigo Company plc's trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms